Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$36.22

16.31 (81.92%)

, BPMC

Blueprint Medicines

$86.00

-3.14 (-3.52%)

10:50
08/13/19
08/13
10:50
08/13/19
10:50

Deciphera INVICTUS results best-case scenario, price target raised at Guggenheim

As previously reported, Guggenheim analyst Michael Schmidt raised his price target for Deciphera (DCPH) to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study of ripretinib in 4L+ GIST, which he believes "significantly exceeded" investors' expectations and validated his bullish thesis and analyses heading into the binary event. The analyst notes that results included a 6.3 months mPFS readout in a setting with no approved therapies and also compare favorably to competitor data from Blueprint Medicines (BPMC) in similar patients. Together with updated Phase 1 ripretinib data across 2L and 3L GISTs, Schmidt thinks these results read-through positively also for the drug's potential in earlier stage GIST patients. Deciphera's Phase 3 INTRIGUE trial in 2L GIST will complete enrolling in the second quarter of 2020, he adds. The analyst has a Buy rating on Deciphera's shares.

DCPH

Deciphera

$36.22

16.31 (81.92%)

BPMC

Blueprint Medicines

$86.00

-3.14 (-3.52%)

  • 13

    Aug

  • 09

    Sep

DCPH Deciphera
$36.22

16.31 (81.92%)

06/10/19
PIPR
06/10/19
NO CHANGE
Target $55
PIPR
Overweight
Piper Jaffray says a buyer of Deciphera after DCC-3116 added to pipeline
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $55 price target on Deciphera following the disclosure of the company's newest preclinical candidate, DCC-3116, an ULK kinase inhibitor important in autophagy initiation. In a research note to investors, Raymond says that given recent advances in KRAS targeting, this target's complementary effects make it an "intriguing" combination agent with the myriad agents approved and in development, adding that he remains a buyer.
07/18/19
DBAB
07/18/19
INITIATION
Target $42
DBAB
Buy
Deciphera initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Deciphera with a Buy rating and $42 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
08/13/19
PIPR
08/13/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera Phase 3 Invictus study a 'best-case' scenario, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views this morning's Phase 3 Invictus study results from Deciphera Pharmaceuticals as a "best-case" scenario. A 27.6 week progression free survival measure was better than the un-adjudicated Phase 1 experience of 24 weeks, and was also statistically significant improved versus placebo, Raymond tells investors in a research note. While some may quibble with a non-statistically significant overall response rate, this "misses the broader point, which is that ripretinib is now not just approvable, but in our view very likely the best-in-class KIT inhibitor" in gastrointestinal stromal tumors, says Raymond. He expects Deciphera shares to "rally sharply" today and keeps an Overweight rating on the name with a $55 price target. The stock in premarket trading is up 122%, or $24.40, to $44.35.
08/13/19
GUGG
08/13/19
NO CHANGE
Target $66
GUGG
Buy
Deciphera price target raised to $66 from $44 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target on shares of Deciphera to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study.
BPMC Blueprint Medicines
$86.00

-3.14 (-3.52%)

06/17/19
STFL
06/17/19
NO CHANGE
STFL
Stifel would be surprised if another suitor tries to outbid Pfizer for Array
After Pfizer (PFE) announced an agreement to acquire Array BioPharma (ARRY) for $48 per share in cash, Stifel analyst Stephen Willey said he views the deal as a "fitting," "logical" and "appropriate" conclusion for Array shareholders and he would be "very surprised" if another suitor tried to compete with a higher priced offer. He believes a "very fair valuation" is implied by the $11.4B price Pfizer has agreed to pay, Willey added. He also sees the deal announcement providing a tailwind for the sector, specifically for small-to-mid cap oncology companies that are "perceived to have achieved some meaningful level of de-risking." As examples, he offers Exelixis (EXEL) and Blueprint Medicines (BPMC), though Willey added that a potentially shortened exclusivity runway could make a deal for Exelixis "a bit harder for a strategic to rationalize."
07/18/19
DBAB
07/18/19
INITIATION
Target $110
DBAB
Buy
Blueprint Medicines initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Blueprint Medicines with a Buy rating and $110 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
07/18/19
BARD
07/18/19
INITIATION
Target $120
BARD
Outperform
Blueprint Medicines initiated with an Outperform at Baird
Baird analyst Michael Ulz started Blueprint Medicines with an Outperform rating and $120 price target.
08/02/19
ADAM
08/02/19
NO CHANGE
Target $120
ADAM
Buy
Blueprint Medicines price target raised to $120 from $105 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Blueprint Medicines to $120 from $105 following recent operational and development updates. She continues to view its pipeline as novel, rationally designed, targeted kinase inhibitors as attractive. Lee reiterated her Buy rating on blueprint Medicines shares.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,815.98

-7.21 (-0.40%)

14:00
08/22/19
08/22
14:00
08/22/19
14:00
Periodicals
Amazon acquires 49% interest in India's Future Coupons, TechCrunch reports »

Amazon has acquired a 49%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BTHE

Boston Therapeutics

$0.00

(0.00%)

13:56
08/22/19
08/22
13:56
08/22/19
13:56
Hot Stocks
Boston Therapeutics BTI320 Phase 2 study achieves full enrollment »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$212.87

0.18 (0.08%)

, BABA

Alibaba

$171.93

-3.26 (-1.86%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Periodicals
EU targets Apple, Google, others with EUR100B wealth fund plan, Politico says »

EU officials want to set…

AAPL

Apple

$212.87

0.18 (0.08%)

BABA

Alibaba

$171.93

-3.26 (-1.86%)

GOOG

Alphabet

$1,191.36

0.57 (0.05%)

GOOGL

Alphabet Class A

$1,192.66

2.4 (0.20%)

AMZN

Amazon.com

$1,815.25

-7.94 (-0.44%)

FB

Facebook

$182.08

-1.48 (-0.81%)

MSFT

Microsoft

$137.45

-1.32 (-0.95%)

BIDU

Baidu

$105.36

-2.55 (-2.36%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

SEDG

SolarEdge

$80.94

-6.93 (-7.89%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Options
SolarEdge put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

13:44
08/22/19
08/22
13:44
08/22/19
13:44
Periodicals
BNP Paribas cutting 500 jobs at securities services arm in France, Reuters says »

BNP Paribas will cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$111.35

-0.32 (-0.29%)

13:39
08/22/19
08/22
13:39
08/22/19
13:39
Syndicate
Breaking Syndicate news story on Entergy »

Entergy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

NTRA

Natera

$30.66

0.25 (0.82%)

13:18
08/22/19
08/22
13:18
08/22/19
13:18
Hot Stocks
Natera reports 'positive' local coverage determination issued by Palmetto MolDX »

Natera announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/22/19
08/22
13:17
08/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/22/19
08/22
13:16
08/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/22/19
08/22
13:15
08/22/19
13:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTRA

Natera

$30.53

0.12 (0.39%)

13:13
08/22/19
08/22
13:13
08/22/19
13:13
Recommendations
Natera analyst commentary at Piper Jaffray »

Piper says Natera gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

13:10
08/22/19
08/22
13:10
08/22/19
13:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD peaked…

AMGN

Amgen

$204.16

0.32 (0.16%)

13:06
08/22/19
08/22
13:06
08/22/19
13:06
Hot Stocks
Amgen granted orphan designation for multiple myeloma treatment »

Amgen was granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

ZIOP

Ziopharm

$5.09

-0.06 (-1.17%)

13:05
08/22/19
08/22
13:05
08/22/19
13:05
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

SNY

Sanofi

$42.69

-0.48 (-1.11%)

13:04
08/22/19
08/22
13:04
08/22/19
13:04
Hot Stocks
Sanofi treatment of systemic sclerosis granted orphan designation »

Sanofi U.S. Service was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

WFC

Wells Fargo

$45.62

0.63 (1.40%)

13:03
08/22/19
08/22
13:03
08/22/19
13:03
Periodicals
Wells Fargo to pay $6.5M to Navajo Nation to settle account suit, Reuters says »

Wells Fargo intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

ILMN

Illumina

$288.00

-2.5 (-0.86%)

13:02
08/22/19
08/22
13:02
08/22/19
13:02
Hot Stocks
Illumina granted orphan designation neuroblastoma management diagnostic »

Illumina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

OSTK

Overstock.com

$21.84

2.34 (12.00%)

12:49
08/22/19
08/22
12:49
08/22/19
12:49
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$21.40

1.9 (9.74%)

12:45
08/22/19
08/22
12:45
08/22/19
12:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.13

-0.71 (-0.35%)

, ALXN

Alexion

$118.04

3.17 (2.76%)

12:43
08/22/19
08/22
12:43
08/22/19
12:43
Recommendations
Amgen, Alexion analyst commentary at Piper Jaffray »

Piper Jaffray says Amgen…

AMGN

Amgen

$203.13

-0.71 (-0.35%)

ALXN

Alexion

$118.04

3.17 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

12:40
08/22/19
08/22
12:40
08/22/19
12:40
General news
Fed funds futures are lower after the hawkish comments »

Fed funds futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.